Related Experiment Video

Updated: May 24, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma

J Yang1, J He, J Wang

  • 1Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jiyang@mdanderson.org

Leukemia
|March 20, 2012
PubMed

Insights

Constitutive activation of p38 mitogen-activated protein kinase in multiple myeloma cells drives bone destruction. Inhibiting p38 in myeloma cells may prevent or treat myeloma-induced osteolytic bone lesions.

Area of Science:

  • Oncology
  • Molecular Biology
  • Bone Biology

Background:

  • Multiple myeloma frequently causes bone destruction, impacting over 80% of patients.
  • Current therapies are insufficient for complete cure or prevention of myeloma-related bone lesions.
  • The precise mechanisms by which myeloma cells mediate bone destruction remain incompletely understood.

Purpose of the Study:

  • To investigate the role of p38 mitogen-activated protein kinase (MAPK) signaling in myeloma-induced osteolysis.
  • To determine if targeting p38 MAPK in myeloma cells can prevent or treat bone lesions.

Main Methods:

  • Assessed p38 MAPK activation in myeloma cell lines and primary patient cells.
  • Utilized mouse models (SCID and SCID-hu mice) by injecting myeloma cells with varying p38 activity.
  • Investigated the effects of p38 inhibition or knockdown on myeloma cell-induced bone destruction and tumor growth.

Main Results:

  • Constitutive p38 MAPK activation was observed in most myeloma cell lines and primary myeloma cells.
  • Myeloma cells with high p38 activity induced significant bone destruction in mouse models.
  • Inhibition or knockdown of p38 in myeloma cells reduced or prevented osteolytic bone lesions without impacting tumor growth or survival.

Conclusions:

  • Constitutive activation of p38 MAPK in myeloma cells is a key driver of myeloma-induced osteolysis.
  • Myeloma cell p38 activity inhibits osteoblastogenesis and promotes osteoclastogenesis.
  • Targeting p38 MAPK in myeloma cells presents a potential therapeutic strategy for managing myeloma bone disease.

More Related Videos

Models of Bone Metastasis08:49

Models of Bone Metastasis

Published on: September 4, 2012

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...